Provided by Tiger Trade Technology Pte. Ltd.

Novartis AG

152.06
-1.7500-1.14%
Pre-market: 159.907.84+5.16%07:39 EDT
Volume:1.29M
Turnover:195.84M
Market Cap:290.13B
PE:22.99
High:152.74
Open:152.60
Low:151.69
Close:153.81
52wk High:170.46
52wk Low:121.57
Shares:1.91B
Float Shares:1.85B
Volume Ratio:1.14
T/O Rate:0.07%
Dividend:4.67
Dividend Rate:3.07%
EPS(TTM):6.61
EPS(LYR):7.15
ROE:30.35%
ROA:10.25%
PB:6.98
PE(LYR):21.27

Loading ...

Anthropic Appoints Novartis CEO Vas Narasimhan to Its Board

Deep News
·
Apr 14

Novartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk

Dow Jones
·
Apr 10

Novartis to Expand Community Health Programs to More Countries

MT Newswires Live
·
Apr 09

AZN, NVO, NVS: What Does Trump’s New 100% Tariff Mean for Pharma Giants?

TIPRANKS
·
Apr 03

Trump Will Impose 100% Tariff on Some Patented Drugs

Tiger Newspress
·
Apr 03

Novartis Likely to Confirm Guidance -- Market Talk

Dow Jones
·
Apr 02

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Ahead of Fresh Economic Data

MT Newswires Live
·
Mar 30

Novartis Says Drug Improves Kidney Function in Patients With Berger's Disease

MT Newswires Live
·
Mar 30

Global Equities Roundup: Market Talk

Dow Jones
·
Mar 30

Novartis to Take Earnings Hit From Generic Competition -- Market Talk

Dow Jones
·
Mar 30

Novartis announces two-year results from Phase III APPLAUSE-IgAN study

TIPRANKS
·
Mar 30

Novartis to buy biotech company Excellergy for up to $2B

TIPRANKS
·
Mar 27

Novartis (NVS) Stock Rises on $2B Excellergy Acquisition to Expand Allergy Portfolio

TIPRANKS
·
Mar 27

Novartis to Acquire US Biotech Firm Excellergy in Deal Worth Up to $2 Billion

Deep News
·
Mar 27

Novartis's Excellergy Payments Should Be Back-End Loaded -- Market Talk

Dow Jones
·
Mar 27

Novartis Acquires Excellergy for $2 Billion to Strengthen Food Allergy and Immune Disorder Portfolio

Stock News
·
Mar 27

Novartis to Acquire Excellergy For Up to $2 Billion

MT Newswires Live
·
Mar 27

Novartis Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Mar 27

Morgan Stanley Sticks to Its Buy Rating for Novartis (NVS)

TIPRANKS
·
Mar 26

Novartis Ag : Morgan Stanley Raises Target Price to $170 From $143

THOMSON REUTERS
·
Mar 26